EGFR and acute lymphoblastic leukemia: ERBB is frequently elevated in Ph+ ALL, and ERBB/HER2/NEU inhibitor lapatinib was synergistic with imatinib and nilotinib (but not dasatinib) on Ph+ ALL cell lines with high ERBB expression (63).